|
|
Vaccine Detail
|
EURIFEL FeLV |
| Vaccine Information |
- Vaccine Name: EURIFEL FeLV
- Target Pathogen: Feline leukemia virus
- Target Disease: Feline leukemia virus infection
- Tradename: EURIFEL FeLV
- Manufacturer: Merial
- Vaccine Ontology ID: VO_0000918
- Type: Recombinant vector vaccine
- Status: Licensed
- Host Species for Licensed Use: Cat
- Env from strain FRA
gene engineering:
- Type: Recombinant protein preparation
- Description: Canarypox-based recombinant vaccine that expresses the FeLV env and gag protective genes (Poulet et al., 2003)
- Detailed Gene Information: Click Here.
- gag
gene engineering:
- Type: Recombinant protein preparation
- Description: Canarypox-based recombinant vaccine that expresses the FeLV env and gag protective genes (Poulet et al., 2003)
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: Canarypox virus-vectored vaccine
|
| Host Response |
|
Cat Response
- Challenge Protocol: Oronasal FeLV challenge
- Efficacy: The vaccine, (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes, is effective against any oronasal FeLV challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe 'in-contact' challenge (Poulet et al., 2003).
|
| References |
Poulet et al., 2003: Poulet H, Brunet S, Boularand C, Guiot AL, Leroy V, Tartaglia J, Minke J, Audonnet JC, Desmettre P. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. The Veterinary record. 2003; 153(5); 141-145. [PubMed: 12934796].
|
|
